Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Mark Laughlin"'
Autor:
Collette Fitzgerald, Janet Pruckler, Maria Karlsson, Patrick Kwan, Lavin Joseph, Hayat Caidi, Mark Laughlin, Rachael D. Aubert
Publikováno v:
Practical Handbook of Microbiology ISBN: 9781003099277
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59993a1f1594c255c752eb3c2818ff93
https://doi.org/10.1201/9781003099277-26
https://doi.org/10.1201/9781003099277-26
Autor:
Andrew Baczkowski, Maureen M. Jonas, Karen F. Murray, Steven R. Martin, Mark Shelton, Y. Lurie, Michael Geffner, Regino P. Gonzalez-Peralta, Barbara Haber, Jean P. Molleston, Thomas Lang, Mark Laughlin, Giorgina Mieli-Vergani, Deirdre Kelly, Samir K. Gupta
Publikováno v:
Hepatology. 42:1010-1018
Chronic hepatitis C virus (HCV) infection is usually asymptomatic in children, but significant liver disease may occur. We evaluated the efficacy, safety, and pharmacokinetics of interferon alfa-2b and ribavirin in children with chronic HCV. We deter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::219fc0f6b3c96b52eda3017b82a8f8e4
https://doi.org/10.1002/hep.20884
https://doi.org/10.1002/hep.20884
Autor:
George Webster, Yoav Lurie, Geoffrey Dusheiko, Ran Oren, Mary L. Jackson, Regine Rouzier-Panis, Mark Laughlin
Publikováno v:
Clinical Gastroenterology and Hepatology. 3:610-615
Pegylated interferon alfa-2b (PEG-IFN-alfa 2b ) has been shown to provide superior efficacy to IFN-alfa 2b in patients with chronic hepatitis C (predominantly genotype 1) infection as measured by viral clearance. This study was conducted to determine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a0b849b0eb62696363e40569ca6bc34
https://doi.org/10.1016/s1542-3565(04)00723-2
https://doi.org/10.1016/s1542-3565(04)00723-2
Autor:
A. Sansone, Monika Martinho, Rachel Courtney, William K. Smith, Suzanne K. Swan, Paul Statkevich, T. Marbury, Mark Laughlin
Publikováno v:
The Journal of Clinical Pharmacology. 45:185-192
Posaconazole is a triazole antifungal in development for the treatment of invasive fungal infections. The authors evaluated the pharmacokinetics and safety of posaconazole in healthy subjects and in those with mild (CL(CR) = 50-80 mL/min), moderate (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::532bf1590c8e7e4d44122269a836a97b
https://doi.org/10.1177/0091270004271402
https://doi.org/10.1177/0091270004271402
Publikováno v:
British Journal of Clinical Pharmacology. 57:218-222
Aims This randomized, crossover, single-dose study evaluated the relative oral bioavailability of posaconazole suspension and coprecipitate tablet formulations. Additionally, the study determined whether systemic exposure to posaconazole was affected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e8fdf5f9c704825278682dcaa8892f7
https://doi.org/10.1046/j.1365-2125.2003.01977.x
https://doi.org/10.1046/j.1365-2125.2003.01977.x
Publikováno v:
Antimicrobial Agents and Chemotherapy. 47:2788-2795
The pharmacokinetics, safety, and tolerability of posaconazole, an investigational triazole antifungal, were evaluated following the administration of rising single and multiple oral doses. A total of 103 healthy adults were enrolled in two phase I t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d4eea51465691f7abc37e17e28607f6
https://doi.org/10.1128/aac.47.9.2788-2795.2003
https://doi.org/10.1128/aac.47.9.2788-2795.2003
Autor:
Stephen R. Indelicato, Josephine Lim, Mark Laughlin, Amin A. Nomeir, Pramila Kumari, Mary Jane Hilbert, Chin-Chung Lin, Hong Kim
Publikováno v:
Journal of Chromatography A. 987:243-248
Posaconazole (SCH 56592) is a novel broad spectrum triazole antifungal agent that is currently in phase III clinical trials for the treatment of systemic fungal infections. This study was initiated to determine if orally administered posaconazole to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fb7c0520ec450c4deb6086620a91b08
https://doi.org/10.1016/s0021-9673(02)01599-6
https://doi.org/10.1016/s0021-9673(02)01599-6
Autor:
Melton B. Affrime, J. Jen, Paul Glue, Carol Chung, Gerald Hajian, Mark Laughlin, Samuel Heft, Samir K. Gupta
Publikováno v:
Clinical Pharmacology & Therapeutics. 72:349-361
Background Combination therapy of ribavirin with interferon alfa-2b and pegylated interferon alfa-2b is currently approved for the treatment of chronic hepatitis C. Approved ribavirin dosages vary from a fixed dosage of 800 mg/d to as much as 1200 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5f53d8f35d52d75eb73b4988bd75c53
https://doi.org/10.1067/mcp.2002.127112
https://doi.org/10.1067/mcp.2002.127112
Autor:
Ronald M. Bukowski, Craig Tendler, F.R.C.P.C. David Cutler M.D., Esther Rose, Mark Laughlin, Paul Statkevich
Publikováno v:
Cancer. 95:389-396
BACKGROUND PEG Intron (pegylated interferon-alpha-2b [IFN-α-2b]; Schering-Plough, Kenilworth, NJ) has demonstrated delayed clearance and increased area under the curve compared with native IFN-α-2b. Studies in patients with chronic hepatitis C infe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cf9d94c30dbc939af1bdc2a6e697025
https://doi.org/10.1002/cncr.10663
https://doi.org/10.1002/cncr.10663
Autor:
Mark Laughlin, Larry Heimark, Amin A. Nomeir, Anil K. Saksena, Raymond G. Lovey, Chin-Chung Lin, Hong Kim
Publikováno v:
Chirality. 12:590-597
SCH 56592 is a novel triazole antifungal agent that is active both orally and intravenously in animal models of infection. This compound is in Phase II-III clinical trials for the treatment of systemic fungal infections. SCH 56592 is a single enantio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6ea96542c88bbf65bd7ad2b511722e2
https://doi.org/10.1002/1520-636x(2000)12:7<590::aid-chir7>3.0.co
https://doi.org/10.1002/1520-636x(2000)12:7<590::aid-chir7>3.0.co